RedHill Biopharma

[Available On-Demand]
RedHill Biopharma (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill’s U.S. commercial sales force is promoting several gastrointestinal drugs, including RedHill’s Talicia® for H. pylori infection and Movantik® for opioid induced constipation. RedHill also has a robust development pipeline with an ongoing Phase 2/3 development program for COVID-19, a Phase 3 study for pulmonary NTM infections and additional Phase 2 and Phase 3 development programs.
Ticker:
RDHL
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Talicia (H.pylori)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Business Officer
RedHill Biopharma Ltd.